Cancer boost
A timely reminder of the need for reform came this past week when we saw a highly effective medicine for women with secondary (metastatic) breast cancer rejected by the Scottish Medicines Consortium (your report, 8 October). This medicine offered good quality extra months of life, which we know is so important for women at this stage of their diagnosis. We will now be working hard to ensure these reforms are carried out in full and to the benefit of women with breast cancer.
James Jopling
Director for Scotland
Breakthrough Breast Cancer